课题基金 / 基金详情

项目摘要

项目成果

NILUFER ERTEKIN-TANER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
I. INSTITUTIONAL CAREER DEVELOPMENT CORE: Project Summary/Abstract The overall objective of the CCaTS KL2 Institutional Career Development Core is to provide superb training to investigators who can assume leadership roles within multidisciplinary collaborative research teams that conduct outstanding clinical and translational science. The KL2 Program is open to individuals with a doctoral degree in a discipline applicable to clinical and translational research and an existing appointment as Mayo Clinic faculty or under consideration for a Mayo Clinic faculty appointment. After a rigorous selection process, successful applicants and their mentoring team formulate a career development plan based on defined core competencies for clinical and translational science. The plan includes appropriate didactic training; experiential and extramural learning opportunities; and a structured, mentored translational research project. The Specific Aims of this renewal application are to 1) recruit and support a diverse group of Scholars with outstanding potential to lead multidisciplinary, collaborative team science; 2) provide tailored educational experiences based on individual career development needs that include appropriate didactics, experiential activities, and a mentored research experience; and 3) foster a community of Scholars, including partnerships with other career development programs, both within Mayo Clinic and nationally. Key strengths of the KL2 Program include a long history of Program graduates having success as translational scientists, a diverse pool of faculty mentors with strong extramurally funded research programs and a record of mentoring prior Scholars, a large and diverse candidate pool subject to a rigorous selection process, a wide range of curricular options offered without charge, novel strategies to create a positive learning environment for all Scholars, multiple networking and community-building opportunities, options for experiential learning, strong institutional support for the transition to independence after Program completion, and a rigorous evaluation program. Although the KL2 Core has a long history of success, we have identified several opportunities for improvement and innovation, both by crafting new initiatives and by modifying existing program elements as guided by the results of our ongoing rigorous evaluation program. Planned enhancements include new required learning experiences in team science, social media, sex as a biological variable, mentoring (including near-peer cascading mentorship), the hidden curriculum, inclusion and developing a positive working environment for staff, and acting as a visiting scholar. Equipping Scholars with skills addressing these key emerging competencies will prepare them for success as CTS investigators.
期刊论文(174)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1177/08850666211069098
发表时间: 2022-08
期刊: Journal of intensive care medicine
影响因子: 3.1
作者: []
通讯作者:
Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer.
乳腺癌女性化疗相关闭经的遗传预测因素。
DOI: 10.1016/j.fertnstert.2019.05.018
发表时间: 2019
期刊: Fertility and sterility
影响因子: 6.7
作者: [Ruddy,KathrynJ, Schaid,DanielJ, Partridge,AnnH, Larson,NicholasB, Batzler,Anthony, Häberle,Lothar, Dittrich,Ralf, Widschwendter,Peter, Fink,Visnja, Bauer,Emanuel, Schwitulla,Judith, Rübner,Matthias, Ekici,ArifB, Aivazova-Fuchs,Viktoria, ]
通讯作者:
Intraoperative Plasma Transfusion Volumes and Outcomes in Cardiac Surgery.
心脏手术中的术中血浆输注量和结果。
DOI: 10.1053/j.jvca.2019.12.049
发表时间: 2020
期刊: Journal of cardiothoracic and vascular anesthesia
影响因子: 2.8
作者: [Smith,MarkM, Kor,DarylJ, Frank,RyanD, Weister,TimothyJ, Dearani,JosephA, Warner,MatthewA]
通讯作者: Warner,MatthewA
Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603).
奥昔布宁与安慰剂治疗患有或不患有乳腺癌的女性潮热:一项随机、双盲临床试验 (ACCRU SC-1603)。
DOI: 10.1093/jncics/pkz088
发表时间: 2020
期刊: JNCI cancer spectrum
影响因子: 4.4
作者: [Leon-Ferre,RobertoA, Novotny,PaulJ, Wolfe,EricG, Faubion,StephanieS, Ruddy,KathrynJ, Flora,Daniel, Dakhil,ChristopherSR, Rowland,KendrithM, Graham,MarkL, Le-Lindqwister,Nguyet, Smith,ThomasJ, Loprinzi,CharlesL]
通讯作者: Loprinzi,CharlesL
100
    Discovering Centrally Linked Peripheral Molecular Signatures of Alzheimer's Disease
    • 批准号:
      10555727
    • 项目类别:
    • 资助金额:
      $97.58万
    • 财政年份:
      2023
    • 负责人:
      NILUFER ERTEKIN-TANER
    • 依托单位:
    Administrative Core
    • 批准号:
      10555724
    • 项目类别:
    • 资助金额:
      $52.77万
    • 财政年份:
      2023
    • 负责人:
      NILUFER ERTEKIN-TANER
    • 依托单位:
    A Systems Approach to Targeting Innate Immunity in AD
    • 批准号:
      10246077
    • 项目类别:
    • 资助金额:
      $323.37万
    • 财政年份:
      2020
    • 负责人:
      NILUFER ERTEKIN-TANER
    • 依托单位:
    Integrating the exposome and methylome to inform brain molecular changes in ADRD across established diverse cohorts.
    • 批准号:
      10657846
    • 项目类别:
    • 资助金额:
      $98.9万
    • 财政年份:
      2020
    • 负责人:
      NILUFER ERTEKIN-TANER
    • 依托单位:
    海外基金